<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E800498F-3137-455C-B5CE-BD6B71148E30"><gtr:id>E800498F-3137-455C-B5CE-BD6B71148E30</gtr:id><gtr:name>EvoCell Ltd</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:department>School of Life Sciences</gtr:department><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E800498F-3137-455C-B5CE-BD6B71148E30"><gtr:id>E800498F-3137-455C-B5CE-BD6B71148E30</gtr:id><gtr:name>EvoCell Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0328B883-9698-43E1-A6DC-ED758E6B07F1"><gtr:id>0328B883-9698-43E1-A6DC-ED758E6B07F1</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>D.</gtr:otherNames><gtr:surname>Johnson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/00CD206D-1F00-4050-ABC8-D4F9DEF94A15"><gtr:id>00CD206D-1F00-4050-ABC8-D4F9DEF94A15</gtr:id><gtr:firstName>Ramiro</gtr:firstName><gtr:surname>Alberio</gtr:surname><gtr:orcidId>0000-0001-6560-3919</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5898DAE4-C0A7-47DC-84FC-18DED8595CCD"><gtr:id>5898DAE4-C0A7-47DC-84FC-18DED8595CCD</gtr:id><gtr:firstName>Keith</gtr:firstName><gtr:otherNames>Henry</gtr:otherNames><gtr:surname>Campbell</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0300350"><gtr:id>8FF209EC-DC8F-41A7-8C33-A75C87C81B4F</gtr:id><gtr:title>A heterologous system for de-differentiation and reprogramming of somatic cells</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0300350</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2007-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>216357</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>EvoCell Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with Evo Cell Ltd.</gtr:description><gtr:id>78151B17-D7CD-4301-BABA-4BB07D1935F8</gtr:id><gtr:impact>NA</gtr:impact><gtr:outcomeId>VkHCFs1ARJo-1</gtr:outcomeId><gtr:partnerContribution>A partnership with the spin-out company EvoCell Ltd. was established in 2005 and is currently ongoing. EvoCell has funded further research for the development of the technology based on reprogramming cells using axoloti oocyte extracts. This collaboration has provided supplementary resources for developing such a challenging project.</gtr:partnerContribution><gtr:piContribution>NA</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Cheltenham Science festival (June 9, 2006). Speaker</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>E255A022-F720-48C6-B16F-6B39C7C695F1</gtr:id><gtr:impact>NA</gtr:impact><gtr:outcomeId>eXJStTtCnrr</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Various interviews Italian Radio/TV/Press (Sept 27-30, 2006).</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>DFC0DFA3-EB13-4D40-9A86-EBD07CFEFF3C</gtr:id><gtr:impact>NA</gtr:impact><gtr:outcomeId>TjkGBPAmb6S</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Radio interview (June 5, 2006)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>217A25C4-3279-4A30-9200-08DFF0CE95A5</gtr:id><gtr:impact>NA</gtr:impact><gtr:outcomeId>G4KwyMny22C</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>270000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EuroSTELLS (Development of a Stem Cell Toolbox)</gtr:description><gtr:fundingOrg>European Science Foundation (ESF)</gtr:fundingOrg><gtr:id>D079B678-5707-4474-932D-8D5E597A9812</gtr:id><gtr:outcomeId>75D48AC2E1A0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A method of producing a reprogrammed cell or reprogrammed cell nucleus, comprising exposing a differentiated cell, or the nucleus of a differentiated cell to a cell or cell extract thereof derived from an oocyte, egg, ovary or early embryo of a cold blooded vertebrate, wherein the cold blooded vertebrate has one or more of the following properties: (i) a primitive vertebrate body plan including laterally projecting ribs and/or spinal projections; (ii) germ cells which do not contain germ plasm; and/or (iii) the oocyte, egg, ovary or early embryo cell or cell from which the cell extract is derived, expresses a highly conserved form of Oct-4 and/or nanog. There is also provided uses of the reprogrammed cells.</gtr:description><gtr:grantRef>G0300350</gtr:grantRef><gtr:id>3F7B4064-B6F3-4A3D-824E-222BB10461B4</gtr:id><gtr:impact>A patent has been filed on the use of Axolotl oocytes for cellular reprogramming. The exclusive use of the technology has been given to EvoCell, a spin-out company from the U. of Nottingham. Other academics will benefit very soon of these technology, since material and cells will be made available as soon as cell lines are established. The pharma industry can benefit immediately by initiating high throughput screening procedures to identify reprogramming molecules. The public/NHS will potentially benefit as soon as some translation studies are carried out with reprogrammed cells (5-10 years).</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>PWHdWJkHzcZ</gtr:outcomeId><gtr:patentId>WO2007010287</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>BIOLOGICAL MATERIALS AND USES THEREOF</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1B9092D8-65DD-499F-80E8-417456F114B9</gtr:id><gtr:title>Reprogramming somatic cells into stem cells.</gtr:title><gtr:parentPublicationTitle>Reproduction (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49a1224b9a6c1b5fe339e711cb8213e6"><gtr:id>49a1224b9a6c1b5fe339e711cb8213e6</gtr:id><gtr:otherNames>Alberio R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1470-1626</gtr:issn><gtr:outcomeId>DC11E863B4A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>147A2A98-A33F-4835-91DD-3AD86346D936</gtr:id><gtr:title>Epigenetic marks in somatic chromatin are remodelled to resemble pluripotent nuclei by amphibian oocyte extracts.</gtr:title><gtr:parentPublicationTitle>Epigenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/159d6761e5304fe9d3331345335db142"><gtr:id>159d6761e5304fe9d3331345335db142</gtr:id><gtr:otherNames>Bian Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1559-2294</gtr:issn><gtr:outcomeId>81096B562A5</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0300350</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>